Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 6/20 | 0.46 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31710569 | 0.89 | KCNA5 (0.50) | KCNA5KDM4ABRD4CREBBPHDAC1 | |
| SCHEMBL4060683 | 0.89 | KCNA5 (0.50) | KCNA5KDM4ABRD4CREBBPHDAC1 | |
| SCHEMBL3415814 | 0.87 | MTNR1A (0.46) | DGAT2MGAT2NPC1RAB9A | |
| SCHEMBL7710607 | 0.84 | KCNA5 (0.52) | KCNA5BDKRB1KDM4ABRD4CREBBP | |
| SCHEMBL25470419 | 0.83 | KCNA5 (0.51) | KCNA5BDKRB1KDM4ABRD4CREBBP | |
| SCHEMBL5477445 | 0.83 | CHRM1 (0.56) | KCNA5KDM4ABRD4CREBBPHDAC1 | |
| SCHEMBL7173368 | 0.83 | MTNR1A (0.50) | DGAT2MGAT2PDK2NPC1RAB9A | |
| SCHEMBL3415342 | 0.83 | ERN1 (0.52) | PDK2HDAC1 | |
| SCHEMBL3413608 | 0.83 | KCNA5 (0.51) | KCNA5BDKRB1KDM4AHDAC1 | |
| SCHEMBL3415738 | 0.82 | CHRM3 (0.51) | BRD4CREBBPHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | KCNA5 2463/4885DGAT2 1165/4885MGAT2 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.